Key Points
- Insider sale: GSK insider Luke Miels sold 4,549 shares on February 9 at an average price of GBX 2,211, for a total of £100,578.39.
- Analysts are mixed—three Buy, three Hold and one Sell—resulting in a consensus rating of "Hold" and an average target price of GBX 1,917.86, with several firms recently raising their targets.
- Key fundamentals: market cap £86.75 billion, P/E 16.17, last quarter EPS GBX 172 (analysts forecast ~GBX 176 for the year), and a 12‑month range of GBX 1,242.50–2,219.
GSK plc (LON:GSK - Get Free Report) insider Julie Brown bought 6 shares of GSK stock in a transaction dated Tuesday, February 10th. The stock was purchased at an average cost of GBX 2,179 per share, for a total transaction of £130.74.
GSK Stock Down 0.8%
Shares of LON:GSK opened at GBX 2,150 on Thursday. GSK plc has a 12 month low of GBX 1,242.50 and a 12 month high of GBX 2,219. The company has a 50-day moving average price of GBX 1,867.42 and a 200 day moving average price of GBX 1,685.32. The company has a market cap of £86.75 billion, a price-to-earnings ratio of 16.17, a PEG ratio of 1.24 and a beta of 0.31. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64.
GSK (LON:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, February 4th. The company reported GBX 172 earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. As a group, equities research analysts predict that GSK plc will post 175.980975 earnings per share for the current year.
Analysts Set New Price Targets
A number of brokerages recently weighed in on GSK. Jefferies Financial Group reiterated a "buy" rating and set a GBX 2,100 price objective on shares of GSK in a report on Wednesday, January 7th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of GSK from GBX 1,600 to GBX 1,675 and gave the company a "hold" rating in a research note on Thursday, January 15th. Berenberg Bank raised their price objective on GSK from GBX 1,600 to GBX 1,660 and gave the stock a "hold" rating in a report on Monday, November 24th. JPMorgan Chase & Co. reissued an "underweight" rating on shares of GSK in a research report on Wednesday, January 7th. Finally, Shore Capital Group restated a "buy" rating and set a GBX 2,300 price target on shares of GSK in a research note on Wednesday, February 4th. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, GSK presently has an average rating of "Hold" and a consensus price target of GBX 1,917.86.
Read Our Latest Stock Report on GSK
About GSK
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
